Liminatus Pharma Stock (NASDAQ:LIMN)


FinancialsChart

Previous Close

$3.02

52W Range

$2.53 - $33.66

50D Avg

$7.35

200D Avg

$8.33

Market Cap

$74.70M

Avg Vol (3M)

$1.28M

Beta

0.52

Div Yield

-

LIMN Company Profile


Liminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

3

IPO Date

May 01, 2025

Website

LIMN Performance


LIMN Financial Summary


Dec 24
Revenue-
Operating Income$-405.00
Net Income$-405.00
EBITDA$-405.00
Basic EPS$-4.05
Diluted EPS$-4.05

Fiscal year ends in Dec 24 | Currency in USD